Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver.

导出 OA

翻译打印收藏纠错

作者： Thiyagarajan,Gopal ^[1] ; Narendra,Kumar ^[1] ; Curtis,Perriotte-Olson ^[1] ; Carol A,Casey ^[2] ; Terrence M,Donohue ^[3] ; Edward N,Harris ^[2] ; Geoffrey,Talmon ^[3] ; Alexander V,Kabanov ^[4] ; Viswanathan,Saraswathi ^[5]

作者单位： Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. ^[1] Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. ^[2] Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, Nebraska. ^[3] Department of Biochemistry, University of Nebraska Lincoln, Lincoln, Nebraska. ^[4] Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska. ^[5] Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina. ^[6]

关键词 AALD catalase cytochrome P450 2E1 ethanol superoxide dismutase